ProCE Banner Activity

MM34: Update on Investigational Antiviral Therapies for COVID-19

Multimedia
In this presentation, Dr. Sharon Lewin reviews recent data on investigational therapies for COVID-19, including TMPRSS2 inhibitors, CRISPR-Cas13, and interferon lambda.

Released: March 18, 2021

Expiration: March 17, 2022

No longer available for credit.

Share

Faculty

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia